Identification of snoRNA SNORA71A as a Novel Biomarker in Prognosis of Hepatocellular Carcinoma

Table 2

Univariate and multivariate analysis of tumor-free survival in HCC patients.

Clinicopathologic parameters	Univariate analysis		Multivariate analysis
	HR (95% CI)		HR (95% CI)
Age (<60 vs. ≥60)	0.734 (0.432-1.246)	0.252
Gender (female vs. male)	1.397 (0.559-3.490)	0.474
Hepatitis B (negative vs. positive)	1.608 (0.763-3.386)	0.212
AFP (<400 vs. ≥400)	1.033 (0.618-1.725)	0.901
Cirrhosis (present vs. absent)	1.172 (0.698-1.968)	0.549
Microvascular invasion (present vs. absent)	1.272 (0.460-3.520)	0.643
Tumor differentiation (low vs. high/moderate)	0.760 (0.457-1.262)	0.289
Capsular invasion (present vs. absent)	1.521 (0.904-2.560)	0.114
Multiple lesions (present vs. absent)	1.783 (0.980-3.242)	0.058	1.189 (0.546-2.593)	0.663
Vessel carcinoma embolus (present vs. absent)	1.699 (0.957-3.016)	0.071	1.384 (0.771-2.485)	0.276
TNM stage (I~II vs. III~IV)	2.006 (1.195-3.369)	0.008	1.577 (0.922-2.699)	0.097
Tumor diameter (<5 cm vs. ≥5 cm)	2.604 (1.402-4.839)	0.002	2.154 (1.140-4.070)	0.018
SNORA71A expression (low vs. high)	0.385 (0.228-0.650)	<0.001	0.450 (0.263-0.770)	0.004

AFP = alpha fetal protein; TNM = tumor-node-metastasis; HR = hazard ratio; was considered statistically significant.